EditorialAccuracy and precision in HER2/neu testing in breast cancer: are we there yet?
References (33)
- et al.
HER2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridizationComparison of results and correlation with survival
Mol Diagn
(2000) - et al.
Suggestions for HER2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridization
Pathology
(2001) - et al.
Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER2/neu) gene status in breast carcinoma
Mod Pathol
(2000) - et al.
HER2/neu testing in breast carcinomaA combined immunohistochemical and fluorescence in situ hybridization approach
Mod Pathol
(2000) - et al.
Defining a test for HER2/neu evaluation in breast cancer in the diagnostic setting
Mod Pathol
(2001) - et al.
Strong HER2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization
Hum Pathol
(2003) - et al.
HER2/neu in breast cancerInterobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescence in situ hybridization
Mod Pathol
(2001) - et al.
Impact of polysomy 17 on HER2/neu immunohistochemistry in breast carcinomas without HER2/neu gene amplification
J Mol Diagn
(2003) - et al.
Current perspectives on HER2 testingA review of national testing guidelines
Mod Pathol
(2003) - et al.
HER2 testing and correlation with efficacy of trastuzumab therapy
Oncology (Huntingt)
(2002)
Detection and quantitation of HER2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
Oncogene
(1996)
Evaluation of HER2/neu gene amplification and overexpressionComparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens
J Clin Oncol
(2002)
Specificity of HercepTest in determining HER2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
J Clin Oncol
(1999)
Effect of formalin tissue fixation and processing on immunohistochemistry
Am J Surg Pathol
(2000)
Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER2/neu in breast cancer
J Clin Oncol
(1999)
HER2/neu gene amplification compared with HER2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
Am J Clin Pathol
(2000)
Cited by (35)
Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer
2022, Journal of Pathology InformaticsCitation Excerpt :In current practice, HER2 status is determined through immunohistochemical and/or in situ hybridization (dual color fluorescence [FISH] or dual bright-field chromogenic in situ hybridization [DISH]) assays.8 For in situ hybridization, the necessity of manual quantification of HER2 gene amplification, while reproducible, remains a time-consuming and expensive process.9 Furthermore, with pathologists facing ever-expanding work responsibilities, combined with a shrinking number of new pathologists entering the field, there is a growing unmet need for tools to assist pathologists in managing their daily work.10–12
HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry
2010, Pathology Research and PracticePrognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer
2007, Experimental and Molecular PathologyImproving accuracy of breast cancer biomarker testing in India
2017, Indian Journal of Medical ResearchDetermination of true ERBB2 Gene amplification in breast cancer by quantitative PCR using a reference and a novel control gene
2016, Applied Immunohistochemistry and Molecular Morphology
Copyright © 2004 Elsevier Inc. All rights reserved.